BioMedWire Stocks

Google Develops AI System to Leverage Sound in Detecting Lung Ailments

Health acoustic sounds contain useful health signals that have the potential to aid in health monitoring as well as disease diagnosis. Recently, scientists at Google Research, in collaboration with researchers at Zambia’s Center of Infectious Disease Research, developed an AI system that can use coughing sounds to diagnose lung disease.

The system, called Health Acoustic Representations (HeAR), is available as a preprint on arXiv.

The investigators started working on the system after healthcare professionals reported that over time, they had learned to tell which patients had coronavirus by how their coughs sounded. For their study, they used an approach similar to the one used to create large-language models. They began by converting human sounds such as a baby and adult coughing, throat clearing, panting, laughing, speaking and breathing, which were obtained from YouTube, into spectrograms.

Once this was done, the researchers blocked a portion of each sound then prompted the system to predict the missing part. This is similar to the way large-language models learn to predict the word that comes next in a sentence. This resulted in a foundation model that the investigators explained could be modified for use in a range of tasks. In their case, the investigators used the system to learn to detect coronavirus and tuberculosis infections.

The investigators compared the accuracy of their system using a standard scale with random guesses. They observed that one data set scored 0.645 on coronavirus detection and 0.739 on tuberculosis detection. This is better, especially when compared to results obtained from other AI systems.

In total, the investigators tested the system with 33 different tasks across six datasets.

In their report, the investigators noted that the reported performance for these tasks leveraged frozen embeddings and linear probes rather than fine-tuning the entire neural network. They then acknowledged that while more research was needed, acoustic testing could someday be used in physicians’ offices to diagnose various lung diseases.

Investigators involved in the study included Pauline Musumali, Solomon Chifwamba, Seke Muzazu, Kachimba Shamaoma, and Francesca Silwamba from Zambia’s Center for Infectious Disease Research; and Yun Liu, Aren Jansen, Rory Pilgrim, Ryan Ehrlich, Timo Kohlberger, Dan Ellis, Eduardo Fonseca, and Marc Wilson from Google Research.

Luyu Wang, Basil Mustafa, Chung-Cheng Chiu, Lucas Smaira and Eric Lau from Google DeepMind provided technical support, guidance and critical feedback to the investigators, while teams from Project Coswara and CoughVID provided datasets for research. The Google Research team also offered hardware and software infrastructure support. The investigators’ findings were reported in arXiv.

As these AI-supported detection tools are taken through the development and commercialization process, patients can rely on existing diagnostic instruments made by companies such as Astrotech Corp. (NASDAQ: ASTC) to obtain definitive diagnoses of any conditions afflicting the patients.

NOTE TO INVESTORS: The latest news and updates relating to Astrotech Corp. (NASDAQ: ASTC) are available in the company’s newsroom at https://ibn.fm/ASTC

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN

Chris@BMW

Share
Published by
Chris@BMW

Recent Posts

Calidi Biotherapeutics Inc. (NYSE American: CLDI) Reports Innovative RTNova Platform Research, Exemplifies Pivotal Role of Research

“Research on the treatment of cancer is fundamental to improving outcomes for all patients affected…

23 hours ago

Adageis Offering Comprehensive Healthcare AI Tools to Support Profitable Shift to Value-Based Care

Adageis offers an AI-powered financial technology platform tailored to healthcare providers seeking a financially positive…

5 days ago

Scientists ID Bacteria That Could Be Behind Multiple Sclerosis Development

A new study focusing on twins has found that individuals with a larger presence of…

5 days ago

How Stem Cells Help in Blood Cancer Treatment

Stem cells are the “master cells” within the body because they can grow into any…

6 days ago

UnitedHealth Records Lower Revenue as Medical Advantage Use Grows

UnitedHealth Group, the largest health insurance firm in the U.S., has reduced its revenue forecast…

1 week ago

Nutriband Inc. (NASDAQ: NTRB): Building a Moat Around Abuse-Deterrent Drug Delivery

Nutriband secures new U.S. trademark and international patents for AVERSA(TM) platform AVERSA(TM) Fentanyl targets $80M–$200M…

1 week ago